Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2015 07:05 ET | Source: Myriad Genetics, Inc.

United States Patent and Trademark Office Grants Patent for Vectra(R) DA

SALT LAKE CITY, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark...
November 17, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Will Present Eight Studies at the 2015 San Antonio Breast Cancer Symposium

New Data on the myChoice® HRD and myRisk™ Hereditary Cancer Tests Will be Highlighted SALT LAKE CITY, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in...
November 16, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad RBM DiscoveryMAP(R) Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes

SALT LAKE CITY, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that its DiscoveryMAP® platform successfully...
November 07, 2015 19:30 ET | Source: Myriad Genetics, Inc.

Crescendo Bioscience Announces That New Studies With Vectra(R) DA Data Will be Presented at the American College of Rheumatology 2015 Annual Meeting

SALT LAKE CITY, Nov. 7, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA to...
November 03, 2015 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results

Total Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk™ Hereditary Cancer Company...
October 28, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the 2015 Credit Suisse Healthcare Conference

SALT LAKE CITY, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 24th...
October 22, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Crescendo Bioscience Highlights New Studies With Vectra(R) DA That Will Be Presented at the American College of Rheumatology 2015 Annual Meeting

SALT LAKE CITY, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on Vectra DA will be presented...
October 21, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Will Highlight New Data on Its myRisk(TM) Hereditary Cancer Test at the National Society of Genetic Counselors Annual Conference

SALT LAKE CITY, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data on its myRisk™...
October 20, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal First Quarter 2016 Financial Results on November 3, 2015

SALT LAKE CITY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal first-quarter 2016 and provide a business...
October 09, 2015 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Present New Data on Its myRisk(TM) Hereditary Cancer Test at the CGA-ICC Annual Meeting

SALT LAKE CITY, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present new data on its...